Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : HELIX BIOPHARMA (HBP:TSE) -- Ignore unavailable to you. Want to Upgrade?

To: WAYNE BALL (guessed password) who wrote (164)	11/5/1998 10:00:00 PM
From: thewiz	Read Replies (2) \| Respond to of 193

Whoops! from 110000 to 0 shares in one day? What gives?

To: WAYNE BALL (guessed password) who wrote (164)	1/7/1999 6:08:00 PM
From: burner	Respond to of 193

Helix receives patent for drug delivery technology Helix Biopharma Corp HBP Shares issued 13,776,415 Jan 6 close $0.33 Thu 7 Jan 99 News Release An anonymous director reports A significant composition patent has been issued to the company by the U.S. Patent Office protecting the core technology used in its Biphasix injectionless drug delivery technology. This new patent adds to the existing portfolio of intellectual property, which includes patents for drug delivery systems, anti-infective therapeutics and molecular sensor technology. The company's Biphasix system, which is capable of delivering a wide variety of pharmaceuticals of varying sizes, weights and solubilities into and through the skin, uses a proprietary, lipid-based, microencapsulation process. Preliminary studies have shown that the Biphasix system may enhance the availability of drugs in the body, leading to improved clinical outcomes. This injectionless drug delivery technology is particularly well suited to biologically derived pharmaceuticals including proteins and DNA, which are typically given by injection. Helix has successfully conducted studies with a number of model compounds such as insulin, interferon-a (widely used in the treatment of a common sexually transmitted disease caused by the human papilloma virus) and prostaglandin E(1) (used in the treatment of erectile dysfunction). These initial applications have estimated potential markets in excess of $4-billion (U.S.) annually.

To: WAYNE BALL (guessed password) who wrote (164)	1/31/1999 12:32:00 PM
From: burner	Read Replies (1) \| Respond to of 193

HELIX BIOPHARMA CORP. NEWS RELEASE TSE & VSE: "HBP" JANUARY 28, 1999 SUCCESSFUL INJECTIONLESS DELIVERY OF VACCINES (Aurora, Ontario) - Dr. Marianna Foldvari, Director of Pharmaceutical Research for Helix BioPharma Corp., and Dr. Lorne Babiuk, Director of the University of Saskatchewan's Veterinary Infectious Disease Organization, reported today at Helix's Annual General Meeting in Toronto that vaccines have been successfully delivered transdermally in mice utilizing the BiphasixTM delivery system. These vaccine results complement the Company's earlier announcement in November 1998 that the BiphasixTM delivery system had been successfully used to deliver a large therapeutic protein, interferon-", transdermally without the need for an injection. Furthermore, vaccine research using proprietary lipid-based delivery systems clearly showed that a single intranasal immunization generated a significant immune response in mice. When these immunized mice were exposed to the disease, they were 15 times more likely to survive than the mice which were not immunized. According to Dr. Foldvari, these results signify a major step forward in the development of the Company's delivery systems for human and veterinary vaccine applications. The market for vaccines is currently in excess of US$ 4 billion worldwide and growing at more than 10% per year. With most vaccines and macromolecular therapeutics being delivered by injection, and more than 500 such large molecules and vaccines in the regulatory process in the United States, the BiphasixTM delivery system has the potential to replace or complement injections by taking molecules of varying sizes into and through the skin. The Toronto and Vancouver Stock Exchanges have not reviewed and do not accept responsibility for the adequacy or accuracy of the content of this News Release. Information contained in this news release includes forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially. Helix BioPharma trades on the TSE and VSE under the symbol "HBP" For further information contact: Investor Relations Helix BioPharma Corp. Tel: (905) 841-2300 ext. 232 Fax: (905) 841-2244 E-mail invrelations@helixbiopharma.ca